01
Evidence package
Clean and verify data,complete laboratory work,run statistics and finishscientific interpretation.
- Final study report
- Manuscripts and publication plan
- Clear evidence hierarchy
Commercial pathway
A disciplined routefrom evidence to launch
T-Booster’s commercial pathway brings scientific reporting, intellectual property, compliant communication, UK GMP supply, controlled market entry and strategic partnerships into one stage-gated plan.
Evidence-ledFinal analysis beforescaled scientific claims.
UK GMP routeManufacturing foundationsand batch learning in place.
Four marketsUK, EU, USA and Bangladeshwith tailored compliance.
Multiple routesDirect launch, distribution,licensing and investment.
Commercial foundations
Development milestonesalready completed
The opportunity is not starting from a concept slide. T-Booster has completed participant involvement, produced a clinical batch and established a UK GMP manufacturing route while final scientific and commercial work continues.
260healthy adults acrossthe clinical programme
66,000capsules produced duringproduct development
UK GMPmanufacturing routealready established
2026target for phasedcommercial launch
Commercial launch engine
Build confidence beforebuilding scale
Each stage has a defined output and decision. The company progresses only when evidence, compliance, product quality, supply and market economics are ready for greater exposure.
Five stage gates
A practical pathway fromevidence to market
The pathway separates work that must be completed before launch from work that is learned through a controlled launch.
02
Protect the asset
Advance patent, trademarkand data-room work, thentranslate the evidence intoresponsible communication.
- IP filing strategy
- Claims substantiation file
- Investor and partner dossier
03
Market-ready product
Finalise specifications,labels, stability, qualityrelease, packaging andmarket compliance.
- GMP supply and batch release
- Market-specific labels
- Forecast and inventory plan
04
Controlled launch
Launch deliberately to learnacquisition, conversion,adherence, retention andservice requirements.
- DTC and selected B2B
- Customer support and feedback
- Adverse-event process
05
Scale proven channels
Scale only after product,demand and unit economicsare clearly understood andrepeatable.
- Pharmacy and retail
- Regional distributors
- Licensing and strategic alliances
Manufacturing readiness
UK GMP production andscale-up capability
A completed UK GMP manufacturing route and a 66,000-capsule clinical batch already demonstrate production capability. Ongoing work covers supply-chain contracting, raw-material sourcing, quality assurance and stability testing, and scale-up planning so commercial volumes can be produced reliably once launch begins.
Market entry strategy
A phased launch acrossfour initial territories
Entry combines founder-led digital marketing, professional and practitioner partnerships, and selected distribution channels, sequenced market by market. Final compliance requirements must be confirmed with qualified regulatory advisers in each territory; the website does not present legal or regulatory advice.
United Kingdom
Position and label T-Booster as a food supplement, not a medicine. Claims must stay within applicable nutrition and health-claim rules and must not imply treatment, prevention or cure of disease.
Commercial focusFounder-led DTC launch, selected practitioners, pharmacy conversations and UK distribution.
European Union
Use authorised health claims under their conditions of use, review every ingredient and dose, and assess whether any component creates novel-food or national notification requirements.
Commercial focusPrioritise selected countries through experienced regulatory and distribution partners.
United States
Complete dietary-ingredient, manufacturing, label and structure-function claim review. Any new dietary ingredient pathway must be assessed before interstate introduction.
Commercial focusDigital-first testing supported by specialist fulfilment, compliance and channel partners.
Bangladesh
Prepare product registration, manufacturing or import documentation, approved ingredient review and claims support under the applicable food-supplement framework.
Commercial focusLeverage clinical visibility, medical-university relationships and local distribution capability.
Growth and partnership opportunity
Investment, licensing andplatform expansion
Beyond initial launch, the opportunity includes strategic investment, territory licensing, retail partnerships and a pipeline for future product development, giving partners multiple ways to participate in T-Booster's long-term commercial growth.
Direct-to-consumer
Direct customer model
Learn messaging, conversion, adherence, repeat purchase and customer-support needs directly.
Distribution
Established channels
Work with consumer-health, pharmacy and regional operators that already understand local channels.
Licensing
Partner-led expansion
Consider exclusive or non-exclusive territory rights with minimum performance commitments.
Strategic investment
Capability-led capital
Prioritise investors who add manufacturing, regulatory, brand, digital or distribution expertise.
Launch decision checklist
Defining commercialreadiness
A disciplined launch decision requires more than finished packaging. These gates protect the customer, the evidence and the company.
✓
Evidence language approved
Public statements follow the evidence hierarchyand complete legal review.
✓
Quality and supply released
Specifications, testing, stability and traceabilitysupport reliable batch release.
✓
Customer journey operational
Ordering, fulfilment, returns and supportare tested before launch.
✓
Economics measurable
Pricing, margin, acquisition and repeat purchasecan be measured clearly.